Expression and purification of recombinant human serum albumin fusion protein with VEGF165b in Pichia pastoris

VEGF165b is an endogenous transcriptional splice variant of VEGF and has been shown to have a therapeutic potency as an anti-cancer agent. In this report, a fusion gene consisting of a human VEGF165b and a human albumin (HSA) gene was constructed and then inserted into a pPIC9k vector. The recombinant fusion protein, rhHSA-VEGF165b, was over expressed in the methylotrophic yeast Pichia pastoris under the control of AOX1 promoter. After induction with methanol, the expression level of rhHSA-VEGF165b was 275 mg/L in broth. The fusion protein rhHSA-VEGF165b was purified to more than 95% purity by using Blue Sepharose Fast Flow and SP Sepharose Fast Flow. Biological activity of the prepared rhHSA-VEGF165b was characterized by transwell migration assay, retaining about 9% of that of unmodified rhVEGF165b on a molar basis. Data from mice show that the serum half-life time of rhHSA-VEGF165b was nearly 20 times longer than that of rhVEGF165b.

► rhHSA-VEGF165b is a fusion protein of human VEGF165b and human albumin.
► rhHSA-VEGF165b was over expressed in Pichia pastoris.
► rhHSA-VEGF165b was purified more than 95% purity.
► rhHSA-VEGF165b retained the activity of rhVEGF165b.
► The half-life time of rhHSA-VEGF165b was 20 times longer than rhVEGF165b.